Physician profile
Kim Pham
NPI 1215509658
$3,524.90
in general payments reported to CMS, 2019-2025
21 companies · $727 in 2025
The $727 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $849 · 2023: $516 · 2024: $1,094 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.85 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $319.45 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $309.21 | 2022-2025 | Cequa |
| Alcon Vision LLC | $272.30 | 2024-2025 | Rocklatan |
| Oyster Point Pharma, INC. | $264.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $260.77 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $205.70 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $204.82 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $184.30 | 2021-2024 | Ce-Marked Kxla System |
| Rxsight INC | $160.25 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Amgen INC. | $122.67 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $116.27 | 2022 | |
| Harrow Eye, LLC | $113.65 | 2024-2025 | Vevye |
| Dompe US, INC. | $113.42 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $109.52 | 2022-2023 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $99.43 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $96.09 | 2021 | |
| Genentech USA, INC. | $71.28 | 2024-2025 | Vabysmo |
| Astellas Pharma US INC | $54.96 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $50.00 | 2025 | |
| Lkc Technologies, INC. | $15.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.